# A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

> **NCT03423628** · PHASE1 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 180 (estimated)

## Conditions studied

- Recurrent Glioblastoma Multiforme
- Primary Glioblastoma Multiforme
- Brain Neoplasms, Malignant
- Leptomeningeal Disease (LMD)

## Interventions

- **RADIATION:** Radiation Therapy
- **DRUG:** AZD1390
- **RADIATION:** Radiation Therapy
- **RADIATION:** Radiation Therapy
- **DRUG:** AZD1390
- **DRUG:** AZD1390

## Key facts

- **NCT ID:** NCT03423628
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-04-02
- **Primary completion:** 2026-09-16
- **Final completion:** 2026-09-16
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03423628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03423628, "A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03423628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*